Cover Image
市場調查報告書

基因治療藥的R&D、收益預測 (2016-2026年):癌症、心血管疾病、眼科疾病、罕見疾病等基因治療藥的展望

Gene Therapy R&D and Revenue Forecasts 2016-2026: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs

出版商 Visiongain Ltd 商品編碼 351066
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
基因治療藥的R&D、收益預測 (2016-2026年):癌症、心血管疾病、眼科疾病、罕見疾病等基因治療藥的展望 Gene Therapy R&D and Revenue Forecasts 2016-2026: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs
出版日期: 2016年01月28日 內容資訊: 英文 145 Pages
簡介

本報告提供已上市的基因治療藥與開發平台趨勢的相關調查,基因治療概要,已上市的主要治療藥與收益預測,各疾病種類的主要趨勢與市場預測,主要企業概要,開發平台趨勢,SWOT分析,相關法律,專家的採訪等彙整資料。

第1章 調查概要

第2章 關於基因治療

  • 基因治療是什麼?
  • 基因治療的各種類型
  • 本報告書除外的產品
  • 基因治療載體

第3章 全球基因治療市場:主要的治療藥、預測

  • 產品概要
  • Gendicine (rAd-p53)
  • Oncorine
  • Glybera
    • 藥價策略
    • 收益預測
  • Neovasculgen
    • 實際成果、收益預測

第4章 全球基因治療市場:各疾病種類的預測

  • 全球基因治療藥市場實際成果
  • 基因治療市場預測
  • 癌症治療
    • 臨床試驗
    • 市場預測
  • 罕見疾病治療
    • 市場預測
  • 心血管疾病治療
    • 市場預測
  • 眼科疾病治療
    • 晚期的基因治療
    • 市場預測
  • 其他治療
    • 市場預測
  • 市場佔有率的變化:癌症的基因治療區分成為市場領導

第5章 主要企業

  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetic Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • 基因治療和大型製藥公司

第6章 研發產品線分析、預測

  • 開發平台
  • 開發平台分析
  • GSK2696273-GSK
  • Collategene (AMG0001)-AnGes MG/Vical
  • BC-819-BioCancell
  • BC-821-BioCancell
  • Lenti-D-Bluebird Bio
  • LentiGlobin (LentiGlobin BB305)-Bluebird Bio
  • SPK-RPE65-Spark Therapeutics
  • SPK-CHM-Spark Therapeutics
  • SPK-FIX-Spark Therapeutics/Pfizer
  • SPK-TPP1- Spark Therapeutics
  • Invossa (TissueGene-C)-TissueGene Inc/Kolon Life Science
  • VM202-DPN-ViroMed
  • 重要的開發平台技術開發
  • 基因治療藥的開發平台的展望

第7章 定性分析、預測

  • SWOT分析
  • 主要地區、各國市場的相關法律

第8章 調查採訪

第9章 總論

  • 目前全球市場的展望
    • 基因治療主要的對象疾病、產品
    • 成長推進因素:龐大的開發中產品
    • 主要地區、企業
  • 基因治療藥市場未來

圖表

目錄
Product Code: PHA0086

Gene Therapies - Discover Revenue Predictions and See How Treating Cancer, Cardiovascular Disorders and Other Chronic Diseases Progresses

What does the future hold for gene therapy? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.

Visiongain's new 2016 report gives you revenue forecasts to 2026 for the world gene therapies market, submarkets and leading products. Avoid missing out. There investigate that applied molecular genetics, discovering its most promising uses.

See what gains are possible. Please read on to explore that industry and discover how high its revenues can go.

Scope of our analysis - the technologies whose potential you discover

In this report visiongain defines gene therapy as products modifying the expression of particular genes or correcting abnormal genes.

Therefore this study excludes some agents that may be considered as gene therapies under wider definitions, such as gene silencing and oligonucleotide therapies, antisense therapy and immune system stimulators.

Forecasts and other analyses showing opportunities in those genetic technologies

Besides revenue forecasting to 2026, our analyses show results, growth rates and market shares. There you find original analysis. Our work also explains research and development. In that new report you gain 46 tables, 25 charts and three interviews.

Now make your searching for data on gene therapies easier. Also save time and benefit your insight and authority. That way you can benefit your research, analysis and decisions, helping you see where progress and money lie.

Stay ahead in knowledge. See what is possible for the therapeutic delivery of nucleic acid polymers into patients' cells to treat diseases. The following sections show how visiongain's new investigation helps your work.

Prospects for the overall world market and segments - what is possible?

What are the secrets of that industry's progress? Along with our prediction of the overall world market value for gene therapies, our study shows you individual revenue forecasting of five submarkets to 2026 at world level, with discussions:

  • Cancer (oncology)
  • Cardiovascular diseases
  • Rare medical conditions, including inherited disorders
  • Ophthalmological disorders
  • Other applications of that genetic biotechnology in human healthcare.

Which segment will achieve highest sales? Which has fastest predicted revenue growth? See how and why those commercial uses in human healthcare will develop, prosper and gain in importance.

For developers, producers and sellers, assess how those next-generation medicines generate revenues. Also gauge potential successes from 2016, assessing the most lucrative applications.

Products - discover sales forecasting for leading gene therapies

Our study shows you individual revenue predictions to 2026 for two marketed products:

  • Glybera
  • Neovasculgen.

That report also discusses these brands: Gendicine and Oncorine. Our analyses include revenue forecasting to 2026 for these six drug candidates:

  • GSK2696273 (GSK)
  • Collategene/AMG0001 (AnGes MG/Vical)
  • BC-819 (BioCancell)
  • Lenti-D (Bluebird Bio)
  • SPK-RPE65 (Spark Therapeutics)
  • Invossa/TissueGene-C (TissueGene/Kolon Life Science).

In particular our investigation discusses 12 leading compounds in development. The market will expand through the approval and launch of many products from 2016.

That way see what is possible. The momentum of gene therapy R&D continues, with reportedly more than 2,000 clinical studies worldwide. Stay ahead in knowledge.

Our study explains what the future holds, discussing issues to help your work.

Developments, challenges and opportunities affecting researchers, producers and users

Our investigation lets you assess trends, R&D and outlooks for gene therapy. There you find discussions of forces, progress and potentials:

  • Overcoming challenges when replacing dysfunctional genes, inactivating (knocking out) mutated DNA and introducing a modified gene
  • Commercial prospects of gene addition, reprogramming and correction, as well as cell elimination
  • Pricing, reimbursement and gaining acceptance of the treatments, expanding their use
  • R&D - assess leading drug candidates, especially for treating cancer, cardiovascular diseases, genetic disorders and other hard-to-treat conditions
  • Changing market shares - applications in oncology becoming more prominent, giving pharmaceutical companies many opportunities.

Our study discusses other influences, including these:

  • Translation of research into marketable products modifying human DNA - gene transfer for therapeutic use, altering the nuclear genome
  • Genomic editing technology and other supporting components
  • Collaborations to develop and launch gene-based products - acquisitions and licensing deals
  • Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
  • Gene therapies for ophthalmologic diseases - next-generation medicines
  • Regulations in the United States, the European Union and Japan - overcoming technological and medical challenges to pass clinical trials.

There you explore commercial strengths, weaknesses, opportunities and threats, assessing advances and prospects. You investigate what helps and restrains developers, producers and marketers of gene therapies, benefiting your authority.

Discover in our report what the past, present and future hold for those cellular technologies.

Gene therapies - what revenue could that overall world market earn in 2020?

From 2016 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for gene therapies will reach $204m in 2020, with potential to multiply further in sales to 2026.

Our report's author said: "That emerging market attracts interest from pharma companies and technology providers, a trend likely to continue. Gene therapies in development will bring in a new era for disease treatment and make a difference in long-term benefits for patients."

Visiongain's new survey examines leading companies in that field. Organisations our investigation discusses include these:

  • Bristol-Myers Squibb
  • Pfizer
  • Bayer Healthcare
  • Novartis
  • GSK
  • uniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics.

Prospects for those medical products, systems and tools are great. From 2016 there will arise many opportunities. Our work explains what is possible, helping you stay ahead in knowledge and influence.

Gene Therapy R&D and Revenue Forecasts 2016-2026 shows data and analysis you find nowhere else

In particular our new report gives you these analyses to help your research, plans, decisions and presentations:

  • Overall world revenue to 2026 - see results and sales potential of the gene therapies industry
  • 5 submarkets' revenues to 2026 - investigate segments at world level, finding the most promising and lucrative applications
  • 8 product revenues to 2026 - discover sales predictions for top medical agents on sale and in development, assessing their potentials
  • R&D on gene therapies - explore progress, finding technological, clinical and commercial outlooks, appraising expected products
  • Activities of established, rising and emerging companies - hear about firms' capabilities, deals, portfolios, advances and prospects
  • Interviews with three organisations - discover views to benefit your work, helping you assess that sector, its participants and potential
  • Analysis of what stimulates and restrains that industry and market - gauge challenges and strengths, helping you compete and succeed.

That investigation shows our interviews with Lysogene, Cell Therapy Catapult and the Human Stem Cells Institute OJSC (HSCI). You receive original analysis by our in-house team in London, UK. Discover what the future holds, helping you stay ahead.

Potential for gene therapies - discover what is possible for that medical technology

With our study you gain business intelligence found only in our work. That way you find where money, progress and opportunities lie. See now what is possible.

Our analysis can benefit your influence and reputation for technological and commercial insight, helping you stay ahead of competitors and succeed.

By trying our new study you are less likely to miss opportunity or fall behind. There you explore trends, R&D and sales predications. Why wait and miss out? Instead stay ahead by getting our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Gene Therapy Market Overview
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methods of the Study
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Gene Therapy

  • 2.1. What is Gene Therapy?
  • 2.2. Types of Gene Therapy
  • 2.3. Products Excluded from the Report
  • 2.4. Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2014-2026

  • 3.1. The World Market for Gene Therapy: Overview of Products
  • 3.2. Gendicine (rAd-p53)-The First Gene Therapy to Market
  • 3.3. Oncorine: Growth is Hindered by Certain Factors
  • 3.4. Glybera: Pricing Will Determine the Future of this Promising Gene Therapy
    • 3.4.1. Glybera Pricing Strategy
    • 3.4.2. Glybera Revenue Forecast, 2014-2026
  • 3.5. Neovasculgen: Russia's First Gene Therapy
    • 3.5.1. Neovasculgen: Historical Performance and Revenue Forecast 2014-2026

4. Gene Therapy World Market and Disease Submarkets, 2014-2026

  • 4.1. The Global Market for Gene Therapy Drug Treatments in 2014
  • 4.2. Gene Therapy Market Forecast, 2014-2026
  • 4.3. Gene Therapy for Cancer
    • 4.3.1. Clinical Trials for Cancer
    • 4.3.2. The Cancer Gene Therapy Treatment Submarket Forecast 2014-2026
  • 4.4. Gene Therapy for Rare Diseases
    • 4.4.1. The Rare Disease Treatment Submarket Forecast 2014-2026
  • 4.5. Gene Therapy for Cardiovascular Diseases
    • 4.5.1. The Cardiovascular Disease Treatment Submarket Forecast 2014-2026
  • 4.6. Gene Therapy for Ophthalmologic Diseases
    • 4.6.1. Advanced Stage Gene Therapies for Ophthalmologic Diseases
    • 4.6.2. The Ophthalmologic Disease Treatment Submarket Forecast 2014-2026
  • 4.7. Gene Therapy for Other Diseases
    • 4.7.1. The Other Disease Treatment Submarket Forecast 2014-2026
  • 4.8. Changing Market Shares: Cancer Disease Gene Therapies Will Eventually Become Market Leader

5. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

  • 5.1. UniQure- the First Commercial Stage Gene Therapy Company in the West
  • 5.2. Biogen-Focusing on Ophthalmologic and Rare Disease Gene Therapies
  • 5.3. Bluebird Bio: Gene Editing Technology
  • 5.4. Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
  • 5.5. Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
  • 5.6. Oxford Biomedica: Collaboration as a Strategy
  • 5.7. GenSight Biologics-Novel Mitochondrial Technology Platform
  • 5.8. Gene Therapy and Big Pharma: Collaborations

6. R&D Pipeline Analysis and Forecasts, 2014-2026

  • 6.1. Pipeline
  • 6.2. Pipeline Analysis
  • 6.3. GSK2696273-GSK
  • 6.4. Collategene (AMG0001)-AnGes MG/Vical
  • 6.5. BC-819-BioCancell
  • 6.6. BC-821-BioCancell
  • 6.7. Lenti-D-Bluebird Bio
  • 6.8. LentiGlobin (LentiGlobin BB305)-Bluebird Bio
  • 6.9. SPK-RPE65-Spark Therapeutics
  • 6.10. SPK-CHM-Spark Therapeutics
  • 6.11. SPK-FIX-Spark Therapeutics/Pfizer
  • 6.12. SPK-TPP1- Spark Therapeutics
  • 6.13. Invossa (TissueGene-C)-TissueGene Inc/Kolon Life Science
  • 6.14. VM202-DPN-ViroMed
  • 6.15. Important Pipeline Technology Developments
  • 6.16. The Future of the Gene Therapy Pipeline

7. Qualitative Analysis of the Gene Therapy Market, 2016-2026

  • 7.1. SWOT Analysis of the Gene Therapy Treatment Market, 2016
  • 7.2. Strengths: A Vast Pipeline for a Wide Range of Indications
  • 7.3. Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
  • 7.4. Opportunities and Threats for the Gene Therapy Drug Market, 2016-2026
  • 7.5. Opportunities: Collaborations and Novel Technologies Will Pave the Way
  • 7.6. Threats: Expensive Drugs with Strict Regulations
  • 7.7. National Markets: Regulation of the Gene Therapy Market
    • 7.7.1. Gene Therapy Regulations: Evolving with the Market
    • 7.7.2. US Regulations: Strict Regulation of a Cautious Market
    • 7.7.3. EU Regulations: One Approval So Far
    • 7.7.4. Japanese Regulations: A Rigorous Process

8. Research Interviews from Our Survey

  • 8.1. Interview with Karen Aiach, Founder and CEO of Lysogene, Neuilly-sur-Seine, France
    • 8.1.1. The Origin of Lysogene and its Focus
    • 8.1.2. Strategy and Challenges for Gene Therapy Development
    • 8.1.3. Regulations and Their Effect on the Future of Gene Therapy Development in the EU
  • 8.2. Interview with Dr Fungayi Chidothe, MD, Senior Business Development Manager, Cell Therapy Catapult, London, UK
    • 8.2.1. Cell Therapy Catapult: Supporting the Translation of Research into Marketable Therapies
    • 8.2.2. Trends in the Gene Therapy Industry
    • 8.2.3. The Challenges of Bringing a Gene Therapy to Market
    • 8.2.4. Regulatory and Reimbursement Concerns for Gene Therapies
    • 8.2.5. The Potential and Promise in Gene Therapy Applications
  • 8.3. Interview with Dr Artur Isaev, CEO of HSCI-Human Stem Cells Institute, Moscow, Russia
    • 8.3.1. The Human Stem Cells Institute: Innovation in Russia
    • 8.3.2. Strategies for Marketing Neovasculgen®
    • 8.3.3. The Benefits of the Developed Versus Emerging Marketplace
    • 8.3.4. Challenges of Producing Gene Therapies and a Future Outlook

9. Conclusions from Our Research and Analysis

  • 9.1. The World Gene Therapy Treatment Market: Current World Outlook
    • 9.1.1. Leading Gene Therapy Treatment Submarkets and Products, 2015-2026
    • 9.1.2. Driver for Growth to 2026: A Vast Pipeline of Gene Therapy Products
    • 9.1.3. Leading Regional Markets and Companies: Partnerships Will Achieve Success
  • 9.2. The Future of the Gene Therapy Treatment Market

List of Tables

  • Table 1.1: Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2013, 2014, and 2015
  • Table 3.1: Approved Gene Therapies, 2015
  • Table 3.2: Glybera Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 3.3: Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2015
  • Table 3.4: Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2014-2026
  • Table 4.1: Leading Gene Therapy Drugs by Revenue ($m), 2015
  • Table 4.2: World Market Forecasts for Gene Therapy by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2014-2026
  • Table 4.3: Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2015
  • Table 4.4: Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2015
  • Table 4.5: Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2015
  • Table 4.6: Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2015
  • Table 4.7: Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2015
  • Table 4.8: Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2015
  • Table 4.9: Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2015
  • Table 4.10: Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2014
  • Table 4.11: Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
  • Table 4.12: Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2015
  • Table 4.13: Rare Diseases Gene Therapy Pipeline, 2015
  • Table 4.14: Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
  • Table 4.15: Cardiovascular Gene Therapy Pipeline, 2015
  • Table 4.16: Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
  • Table 4.17: Preclinical Ophthalmologic Pipeline, 2015
  • Table 4.18: Clinical Ophthalmologic Pipeline, 2015
  • Table 4.19: Additional Products in the Clinical Ophthalmologic Pipeline, 2015
  • Table 4.20: Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
  • Table 4.21: Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2026
  • Table 4.22: Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2014-2020
  • Table 4.23: Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2021-2026
  • Table 5.1: uniQure Pipeline, 2015
  • Table 5.2: Spark Therapeutics Collaborations, 2015
  • Table 5.3: Selected Big Pharma Collaborations in Gene Therapy, 2015
  • Table 6.1: Promising Gene Therapies in Development, 2015
  • Table 6.2: Gene Therapies in Phase 3, 2015
  • Table 6.3: GSK2696273 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 6.4: Collategene Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 6.5: BC-819 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 6.6: Lenti-D Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 6.7: SPK-RPE65 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 6.8: Invossa Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2014-2026
  • Table 7.1: Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2016
  • Table 7.2: Gene Therapy Pipeline for Neurodegenerative Diseases, 2015
  • Table 7.3: Gene Therapy Pipeline for Metabolic Diseases, 2015
  • Table 7.4: Gene Therapy Pipeline for Musculoskeletal Diseases, 2015
  • Table 7.5: Gene Therapy Pipeline for Viral Diseases, 2015
  • Table 7.6: Opportunities and Threats of the Gene Therapy Drug Market, 2016
  • Table 7.7: Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2015
  • Table 9.1: Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2014, 2016, 2020 and 2026

List of Figures

  • Figure 1.1: Global Gene Therapy Treatment Market Segmentation Overview, 2016
  • Figure 2.1: Vectors Used in Gene Therapy Clinical Trials, 2015
  • Figure 3.1: Glybera Forecast, Revenue ($m), 2014-2026
  • Figure 3.2: Neovasculgen Forecast, Revenue ($m), 2014-2026
  • Figure 4.1: Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2014-2026
  • Figure 4.2: Cancer Gene Therapy Pipeline by Phase of Development, 2015
  • Figure 4.3: Global Gene Therapy Market: Market Shares (%) by Indication, 2014
  • Figure 4.4: Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2014-2026
  • Figure 4.5: Global Gene Therapy Market: Market Shares (%) by Indication, 2015
  • Figure 4.6: Rare Diseases Gene Therapy Pipeline by Phase of Development, 2015
  • Figure 4.7: Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2014-2026
  • Figure 4.8: Cardiovascular Gene Therapy Pipeline by Phase of Development, 2015
  • Figure 4.9: Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2014-2026
  • Figure 4.10: Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2014-2026
  • Figure 4.11: Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2014-2026
  • Figure 4.12: Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2020
  • Figure 4.13: Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2026
  • Figure 6.1: Gene Therapies in Clinical Development by Phase, 2015
  • Figure 6.2: GSK2696273 Forecast, Revenue ($m), 2014-2026
  • Figure 6.3: Collategene Forecast, Revenue ($m), 2014-2026
  • Figure 6.4: BC-819 Forecast , Revenue ($m), 2014-2026
  • Figure 6.5: Lenti-D Forecast, Revenue ($m), 2014-2026
  • Figure 6.6: SPK-RPE65 Forecast, Revenue ($m), 2014-2026
  • Figure 6.7: Invossa Forecast, Revenue ($m), 2014-2026
  • Figure 9.1: Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2014, 2016, 2020, and 2026

Companies Listed

  • 4DMT (4D Molecular Therapeutics)
  • Abeona
  • AGTC (Applied Genetics Technologies Corporation)
  • AMT (Amsterdam Molecular Therapeutics)
  • AnGes MG
  • ASCO (American Society of Clinical Oncology)
  • ASI (Agency for Strategic Initiatives)
  • Asklepios BioPharma
  • AstraZeneca
  • Audentes Therapeutics
  • Avalanche Biotech
  • Bayer Healthcare
  • Beijing Northland Biotech Co
  • Benda Pharmaceutical
  • Benitec Biopharma
  • BioCancell
  • Biogen
  • Biogen Idec
  • Bluebird Bio
  • BMS (Bristol-Myers Squibb)
  • Broad Institute/Whitehead Institute
  • CAT (Committee for Advanced Therapies)
  • CBER (Center for Biologics Evaluation and Research)
  • Celgene
  • Cell Therapy Catapult
  • Cellectis
  • Chiesi Farmaceutici
  • CHMP (Committee for Medicinal Products for Human Use)
  • CHOP (The Children's Hospital of Philadelphia)
  • Clearside Biomedical
  • Convergence Pharmaceuticals
  • Daiichi Sankyo
  • DCGI (Drugs Controller General of India)
  • DHHS (Department of Health and Human Services)
  • Dimension Therapeutics
  • DMC (Data Monitoring Committee)
  • Editas Medicine
  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • Fondazione Telethon
  • Francis Crick Institute
  • Genable Technologies Ltd
  • Genethon
  • GenSight Biologics
  • GenVec
  • Google
  • GSK (GlaxoSmithKline)
  • Henry Ford Health System
  • HSCI (Human Stem Cells Institute)
  • HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),
  • ImaginAb
  • Immune Design Corp
  • InoCard
  • Inovio
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
  • Intellia Therapeutics
  • Invetech
  • IRB (Institutional Review Boards)
  • Kite Pharma
  • Kolon Group
  • Kolon Life Science
  • Lysogene
  • MFDS (Korean Ministry of Food and Drug Safety)
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • Ministry of Health Commission
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralgene
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • NightstaRx
  • NIH (National Institutes of Health)
  • Northwestern Memorial Hospital
  • Novartis
  • OHRP (Office for Human Research Protections)
  • OXB (Oxford Biomedica)
  • Pfizer
  • PMDA (Pharmaceuticals and Medical Devices Agency)
  • PNP Therapeutics
  • Precision Genome Engineering Inc aka Pregenen
  • ProNai
  • Protek Group
  • RAC (Recombinant DNA Advisory Committee)
  • Raffaele Hospital
  • RCGM (Review Committee of Genetic Manipulation)
  • REGENX Biosciences
  • Renova Therapeutics
  • Roche
  • Roszdravnadzor
  • Russian Ministry of Healthcare and Social Development
  • Sangamo Biosciences
  • Sanofi
  • Sarepta Therapeutics
  • SFDA (State Food and Drug Administration of China)
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • SMC (Scottish Medicines Consortium)
  • Sotex Pharm Firm
  • Spark Therapeutics
  • SynerGene Therapeutics
  • Takara Bio
  • TAP Biosystems
  • The Fund for Promotion of Small Innovative Enterprises in Science and Technology
  • The IGI (Innovative Genomics Initiative)
  • The Innovative Genomics Initiative
  • The Walter and Eliza Hall Institute
  • The Wellcome Trust Sanger Institute
  • Thermo Fisher Scientific
  • TissueGene
  • ToolGen
  • UC Berkeley
  • UC San Francisco
  • uniQure
  • US Business Innovation Network
  • Vertex Pharmaceuticals
  • Vical Incorporated
  • ViroMed
  • VM Biopharma
  • Voyage Therapeutics
  • WFH (World Federation of Hemophilia)
  • WHO (World Health Organization)
Back to Top